What is Artificial Intelligence In Genomics Market?
Although genomic medicine has achieved great advances in recent years, the clinical use of genomics is still evolving as new understanding and technology emerge. One key problem is making sense of exceptionally huge amounts of genomic sequence data and properly integrating and examining it with other relevant information, such as other molecular or clinical data. AI-based computer vision methods are set to change image-based diagnostics in clinical diagnostics, while other AI subtypes have begun to show comparable promise in diverse diagnostic modalities. Deep learning is a sort of AI technique that is used to handle vast and complicated genomic datasets in particular fields, such as clinical genomics.
Highlights from Artificial Intelligence In Genomics Market Study
Attributes | Details |
---|
Study Period | 2018-202 |
Base Year | 2022 |
Unit | Value (USD Million) |
Key Companies Profiled | IBM Corporation (United States), Microsoft Corporation (United States), NVIDIA Corporation (United States), Deep Genomics (Canada), BenevolentAI (United Kingdom), Fabric Genomics Inc. (United States), Verge Genomics (United States), Cambridge Cancer Genomics (United Kingdom), Sophia Genetics (United States) and Data4Cure Inc. (United States) |
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Artificial Intelligence In Genomics market throughout the forecasted period.
IBM Corporation (United States), Microsoft Corporation (United States), NVIDIA Corporation (United States), Deep Genomics (Canada), BenevolentAI (United Kingdom), Fabric Genomics Inc. (United States), Verge Genomics (United States), Cambridge Cancer Genomics (United Kingdom), Sophia Genetics (United States) and Data4Cure Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Diploid (Belgium), Genoox Ltd. (United States), Lifebit (United Kingdom), Empiric Logic (Ireland) and PrecisionLife Ltd (United Kingdom). Artificial Intelligence In Genomics Market Segmentation:
Scope | Sub-Segments |
---|
Application / End User | Diagnostics, Drug Discovery & Development, Precision Medicine, Agriculture & Animal Research and Other |
Technology | Deep Learning,Reinforcement Learning,Supervised Learning,Unsupervised Learning,Others |
End Use | Hospitals,Specialty Clinics |
Functions | Genome Sequencing,Gene Editing,Clinical Workflows,Predictive Genetic Testing |
Component | Software,Services (Managed, Professional) |
On the basis of geography, the market of Artificial Intelligence In Genomics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
Rising Adoption of AI in Precision Medicine Segment
Market Growth Drivers:
High Investments in AI for Genomics and Growth in Healthcare Infrastructure
Challenges:
Data Theft or Leakage and High Initial Investment
Restraints:
Technical Glitches and Errors
Opportunities:
Increasing Penetration Across Emerging regions
Key Target Audience
Genomics Companies, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
Market Leaders & Development Strategies
On 17th December, 2020 - Illumina, Emedgene Launch AI-Based Rare Disease Interpretation Partnership to Integrate Automated Interpretation of Rare Genetic Disease Data into Illumina’s TruSight Software Suite.